Focus: Janux Therapeutics is a public-stage biotechnology company focused on immunotherapies for cancer, headquartered in San Diego with a clinical-stage pipeline in oncology and autoimmune indications.
Profile data last refreshed 15m ago · AI intelligence enriched 2mo ago
Cooling — net -6 jobs in 30d
1 added, 7 removed. Slower than typical.
Janux is a high-risk/high-reward scientific opportunity best suited for researchers prioritizing innovative immunotherapy platform over near-term career stability.
Help build intelligence for Janux Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Janux Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
JANX Financials: Revenue Breakdown, Margins & Competitor Comparison Intellectia AI
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake - Stock Titan
Janus Henderson (JANX) discloses 4.2M shares, 6.9% passive stake Stock Titan
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX) GuruFocus
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 - Stock Titan
Janux Therapeutics (JANX) VP sells 2,038 shares at $14.17 Stock Titan
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts - simplywall.st
Bullish: Analysts Just Made A Meaningful Upgrade To Their Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasts simplywall.st
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics - Stock Titan
State Street (JANX) reports 2.46M shares, a 4.1% stake in Janux Therapeutics Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo